Comparison of Blood Levels of HTL0016878 From an Oral Capsule and an Oral Solution

Healthy Subjects Clinical Trial

Official title:

Phase 1, Randomised, Open-label, 3-period Crossover, Single Dose Study in Healthy Subjects, to Assess Relative Bioavailability From an Oral Capsule of HTL0016878 Citrate Salt Versus an Oral Solution of HTL0016878 Hydrochloride Salt

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04935320
• Other study ID #: HTL0016878-102
• Secondary ID: 18-0182018-00368
• Status: Completed
• Phase: Phase 1
• Start date: July 27, 2021
• Est. completion date: October 29, 2021

Study information

• Verified date: November 2021
• Source: Heptares Therapeutics Limited
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a randomised, open-label, 3-period, crossover single dose study to assess the relative bioavailability of two formulations of HTL0016878: an oral solution of HCl salt form (the reference product) and an oral capsule containing citrate salt (the test product); and of the effect of food on the pharmacokinetics of the capsule formulation.

Description:

Fifteen healthy male or female subjects will be enrolled. Each subject will have 3 study sessions and receive a single oral dose of 10 mg HTL0016878 on Day 1 of each study session. Subjects will receive the HTL0016878.HCl oral solution in the fasted state in 1 session, and the HTL0016878.citrate capsule, in the fasted state and after a high-fat meal, respectively, in the other 2 sessions. Each subject will be randomised to 1 of 3 treatment sequences (5 subjects to each sequence). There will be a washout of at least 10 days between doses. Subjects will be screened within 35 days before their first dose of HTL0016878. In each study session, subjects will be resident on the ward from the day before dosing (Day -1) until completion of procedures 72 h after their dose (Day 4). Subjects will return for a follow up visit 10-13 days after their final dose of trial medication.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: October 29, 2021
• Est. primary completion date: October 29, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

1. Healthy male or females, aged 18-50 years

2. Female subjects must agree to use highly effective contraception

3. Weigh 60 kg or more, with a BMI in the range 18.0-30.0 kg/m2

4. Sufficient intelligence to understand the nature of the trial

5. Willingness to give written consent to participate

6. Agree to use the contraception requirements of the trial

7. Agree not to donate blood or blood products during the study and for up to 3 months after the administration of the trial medication

8. Willingness to give written consent to have data entered into The Overvolunteering Prevention System

Exclusion Criteria:

1. Woman who is pregnant or lactating

2. Clinically relevant abnormal history, physical findings, ECG, or laboratory values

3. Presence or history of acute or chronic illness, or mental health problem

4. Impaired neurological, endocrine, thyroid, cardiovascular, respiratory, gastrointestinal, hepatic or renal function, diabetes mellitus, coronary heart disease, or history of any psychiatric disorder or psychotic mental illness

5. Cancer during the 5 years before screening

6. Supine blood pressure and heart rate outside the ranges: 90-140 mm Hg systolic and 50-90 mm Hg diastolic blood pressure; heart rate 45-80 beats/min

7. Supine QT interval (QTcF) outside the ranges 300-450 msec (men) and 300-470 msec (women)

8. Personal or family history of long QT syndrome or family sudden death

9. Positive test for hepatitis B, hepatitis C or HIV

10. Aspartate aminotransferase, alanine aminotransferase, gamma glutamyl transferase or total bilirubin levels > 1.5 times the upper limit of normal

11. Creatinine clearance < 80 mL/min/1.73 m2

12. Presence or history of drug or alcohol abuse in the past 5 years; or regular intake of more than 21 units of alcohol weekly (for men) or 14 units of alcohol weekly (for women); or use of cigarettes, tobacco and/or nicotine-containing products during the 3 months before dosing

13. Evidence of drug abuse or positive alcohol or cotinine test results

14. Positive pregnancy test

15. Habitual and heavy consumption of caffeinated beverages

16. Use of a prescription or over-the-counter medicine, any herbal remedy, or nutritional supplement

17. Receipt of a vaccine against COVID-19 in the 14 days before dosing

18. Received live attenuated vaccination within 6 weeks prior to Screening

19. History of severe allergies

20. Use of any drugs that are inhibitors of CYP2D6

21. Poor metaboliser of CYP2D6

22. History of epilepsy or seizures

23. Any disease associated with cognitive impairment and/or psychosis

24. Suicidal thoughts or ideation, or insomnia

25. Any history of mental illness (including anxiety, depression), which required medical intervention

26. Presence or history of severe adverse reaction to any drug

27. Surgery or medical condition that might affect absorption of medicines

28. Receipt of an investigational product as part of another clinical trial within the 3 months before dosing in this study

29. Receipt of HTL0016878 in a previous clinical trial

30. Loss of more than 400 mL blood during the 3 months before dosing

31. Unwilling to eat a high-fat breakfast

32. Possibility that the volunteer will not cooperate with the requirements of the protocol

33. Objection by GP to volunteer entering trial

Related Conditions & MeSH terms

• Healthy Subjects

Intervention

Drug:
• HTL0016878.HCl Solution 10 mg
Oral solution fasted
• HTL0016878.Citrate Capsule 10 mg
Oral capsule fed or fasted

Locations

Country	Name	City	State
United Kingdom	Hammersmith Medicines Research Ltd (HMR)	London

Sponsors (1)

Lead Sponsor	Collaborator
Heptares Therapeutics Limited

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Concentration of HTL0016878 in plasma Cmax	Pharmacokinetics	0-72 hours
Primary	Concentration of HTL0016878 in plasma AUC	Pharmacokinetics	0-72 hours
Secondary	Treatment Emergent Adverse Events	Safety and Tolerability	Baseline up to 13 days post-dose